Canada's Best: Enbridge, BCE, Telus, and Brookfield
Investors seeking exposure outside of the U.S. may consider Canadian-based stocks on the TSX.Last week, Enbridge posted first-quarter non-GAAP earnings of C$1.03 a share. It reiterated its 2025 financial guidance. It expects DCF per share of between C$5.50 and C$5.90. Growth from 2023 through 2026 will be between 7% and 9%. Income investors may consider TC Energy (TRP) and PPL (PPL), both of which are in the pipeline sector.BCE (BCE) finally cut its dividend when it announced first-quarter results. Shares now pay a $0.4375 quarterly or $1.75 a year. This is down from $3.99 annually. BCE stock rose after PSP Investments committed $1.5 billion to its Ziply Fiber acquisition. BCE is buying Ziply for $3.6 billion. Ziply has around 1.8 million residential and business locations.Telus (TU) spiked to the $16 resistance level on the NYSE, up by 7.10% on May 9. It raised its dividend by 3.5% after reporting its first-quarter results. Revenue grew by C$5.05 billion, up by 2.4% Y/Y.Brookfield (BAM) is the most compelling investment. In Q1, revenue was $1.08 billion. Fees increased to $698 million, up from $649 million sequentially. Watch for BAM stock to trade above $60 on the NYSE in the weeks ahead. Despite its overvaluation, BAM stock offers growth and profitability. Momentum continues to lift the stock.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


